American International Group, Inc. (NYSE:AIG) today announced the
release of its 2013 Corporate Citizenship Report, which showcases the
company’s governance, environmental, and social performance, as well as
its commitment to long-term sustainability.
Alcoa Inc. (AA) said Monday it expects to book charges totaling $170 million to $180 million after-tax in the third quarter to cover the costs of the permanent closure of its Portovesme aluminum smelter in Italy.
Alcoa (NYSE: AA), the inventor and global leader of forged aluminum
wheels, said that it will roll out its lightest heavy-duty truck wheel
in Europe to help fleets increase payload and fuel efficiency.
BOTHELL, Wash., June 27, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc., ("Alder") (Nasdaq:ALDR) , a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced that Alder will be added to the Russell 3000® Index at the close of the market today, Friday, June 27, 2014 when Russell Investments reconstitutes its set of U.S. and global equity indexes.
plc (NASDAQ: ALKS) today announced the initiation of FORWARD-5, the
third of three core efficacy studies planned in the pivotal clinical
program for ALKS 5461, a once-daily, oral investigational medicine with
a novel mechanism of action for the adjunctive treatment of major
depressive disorder (MDD). The study will evaluate the efficacy and
safety of ALKS 5461 in patients suffering from MDD who have had an
inadequate response to commonly prescribed drugs for depression,
including selective serotonin reuptake inhibitors (SSRIs) or
serotonin-norepinephrine reuptake inhibitors (SNRIs). Approximately
two-thirds of patients who are diagnosed with MDD do not adequately
respond to initial antidepressant therapy.
Inc. (NYSE: AGN) (“Allergan”) and TARIS
Holdings LLC today announced that Allergan has closed a transaction
to acquire worldwide rights to TARIS Biomedical’s ® (“TARIS”)
lead program, LiRIS ® , which is currently in Phase 2 trials
for the treatment of interstitial cystitis / bladder pain syndrome
(IC/BPS). Allergan paid $67.5 million in cash upfront, subject to
certain adjustments and holdbacks.
NEW YORK (MarketWatch) -- Allergan Inc. shares (AGN) rose almost 2% in premarket trade Monday, after the Botox maker reported better-than-expected second-quarter profit and sales and said it is cutting 1,500 jobs, or 13% of its workforce, in a restructuring.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.